The research team, led by investigators at Shandong University and collaborating institutions across China, set out to answer a question that has puzzled oncologists for years: how do colorectal cancer cells that survive chemotherapy manage to keep their mitochondria, the cellular power plants, in working order? Drug-tolerant persister cells are known to enter a reversible adaptive state, rather than acquiring permanent genetic resistance mutations, which makes them especially insidious. When therapy stops, these cells can resume proliferation and regenerate the tumor with its original drug sensitivity intact. The researchers built a comprehensive experimental system to catch these cells in the act, using patient-derived xenografts, organoids grown from patient tumors, conventional colorectal cancer cell lines, and cell line-derived xenografts in animal models.

What they observed in the surviving cells was a profound metabolic transformation. The persister cells showed markedly reduced proliferation without a corresponding increase in apoptosis, the programmed cell death that chemotherapy is designed to trigger. When the researchers withdrew the drugs, the cells resumed growth, confirming that the tolerant state was genuinely reversible. At the metabolic level, the persister cells suppressed glycolysis, the sugar-burning pathway that most cancer cells rely on heavily, and produced far less lactate, the acidic byproduct of that pathway. Instead, they became increasingly dependent on oxidative phosphorylation, the more efficient mitochondrial process that generates cellular energy using oxygen. This metabolic shift was accompanied by a striking activation of mitophagy, the cellular quality-control system that selectively recycles damaged mitochondria.

The centerpiece of the discovery is a protein called UQCRC2, or ubiquinol-cytochrome c reductase core protein 2, a structural component of complex III in the mitochondrial electron transport chain. The researchers found that UQCRC2 accumulated in the drug-tolerant persister cells, where it supported Parkin and SQSTM1-associated mitophagy and enabled the residual cells to survive. But the truly novel element lies in how UQCRC2 is regulated. The team employed an emerging field of post-translational modification research known as lactylomics, using global mass-spectrometry-based profiling to map lysine lactylation sites, a chemical tagging process in which lactate-derived lactyl groups attach to lysine residues on proteins. Because the persister cells produced less lactate, the overall level of lysine lactylation across the proteome dropped, and specifically, lactylation of UQCRC2 at the amino acid lysine 430 declined sharply.

Here the story takes a turn worthy of a molecular thriller. When UQCRC2 is heavily lactylated at position 430, the modified protein becomes a target for K48-linked ubiquitination, a molecular tag that condemns proteins to destruction by the proteasome, the cell’s waste-disposal machinery. Reduced lactylation therefore protects UQCRC2 from degradation and allows it to accumulate. The researchers identified the enzyme responsible for removing the lactyl tag: SIRT1, a member of the sirtuin family of NAD-dependent deacylases that has long been associated with longevity, stress resistance, and metabolic regulation. Through a cell-free delactylation assay, the team demonstrated that SIRT1 directly removes the lactylation from UQCRC2 at lysine 430 in a manner dependent on NAD, the cellular energy carrier. This delactylation stabilizes UQCRC2, preserving mitochondrial function and fueling the mitophagy program that keeps the persister cells alive.

The functional consequences of this pathway were confirmed through a series of genetic and pharmacological experiments. When the researchers depleted PINK1, the kinase that initiates the mitophagy cascade, or knocked down UQCRC2 itself, the survival of the residual drug-tolerant cells plummeted and tumor regrowth was significantly delayed. Inhibiting SIRT1, either genetically or with drugs, produced the same effect, effectively collapsing the survival mechanism that the persister cells depend upon. These results suggest that the SIRT1-UQCRC2 axis represents a genuine therapeutic vulnerability, a chink in the armor of chemotherapy-tolerant cells that could be exploited to prevent the outgrowth of tumors after treatment.

Perhaps the most clinically significant finding came from analyses of actual patient samples. Among chemotherapy-responsive patients with advanced colorectal cancer, low expression of the UQCRC2-K430 lactylation mark in tumor tissue remained associated with poorer overall survival even after multivariable statistical adjustment. The researchers also examined paired samples of circulating tumor cells, rare cancer cells that travel through the bloodstream, collected from patients before and after chemotherapy exposure. In these paired samples, increased SIRT1 expression or decreased UQCRC2-K430 lactylation after chemotherapy was associated with shorter progression-free survival. This pattern suggests that the molecular signature of the persister state, detectable in a simple blood-based assay, could serve as an early warning system identifying patients whose residual disease is primed for relapse.

The methodological breadth of the study deserves particular attention. By integrating whole-exome sequencing with transcriptomic, proteomic, metabolomic, and lactylomic analyses, the researchers were able to triangulate the mechanism from multiple independent angles, ruling out genetic mutation as the driver and instead pointing to a reversible epiproteomic program. Whole-exome sequencing confirmed that the persister cells had not acquired new resistance mutations, while the multi-omic profiling revealed the coordinated metabolic and post-translational remodeling that defines the tolerant state. Metabolic assays measuring oxygen consumption and extracellular acidification rates quantified the shift from glycolysis to oxidative phosphorylation, while protein stability and ubiquitination analyses traced the fate of UQCRC2 through the degradation pathway.

The broader implications of this work extend well beyond colorectal cancer. Drug-tolerant persister cells have been implicated in treatment failure across many tumor types, and the discovery that lysine lactylation functions as a metabolic sensor linking glycolytic output to mitochondrial quality control provides a unifying framework for understanding how cancer cells weather therapeutic stress. Lactate, long dismissed as a mere metabolic waste product, is increasingly recognized as a signaling molecule, and this study adds a striking new dimension to that picture: lactate levels directly tune the stability of a core respiratory protein, thereby determining whether a cell can maintain the mitochondrial infrastructure needed to survive chemotherapy. The finding also positions sirtuins, and SIRT1 in particular, as enzymatic gatekeepers of this lactylation-dependent survival program, raising the prospect that existing and experimental SIRT1 inhibitors could be repurposed as anti-persister agents.

For patients, the road from laboratory discovery to clinical application is long, but this study offers concrete waypoints. The identification of UQCRC2-K430 lactylation as a candidate biomarker of chemotherapy-associated residual disease opens the door to trials that could monitor this mark in circulating tumor cells during treatment, potentially allowing oncologists to intervene before overt relapse occurs. Therapeutic strategies that combine standard FOLFOXIRI chemotherapy with agents that disrupt the SIRT1-UQCRC2-mitophagy axis could, in principle, eliminate the reservoir of persister cells that currently seed tumor regrowth. As the authors conclude, this low-lactate, SIRT1-regulated mechanism couples metabolic suppression to mitochondrial quality control and enables reversible chemotherapy tolerance, and it now stands as one of the most mechanistically complete portraits of drug tolerance assembled in any cancer type to date. The study was supported by the National Natural Science Foundation of China and multiple Chinese research foundations, and the full open-access article is available in Molecular Cancer.

Subject of Research: Lactylation-mediated mitophagy in colorectal cancer drug tolerance during chemotherapy

Article Title: UQCRC2 lactylation-mediated mitophagy orchestrates colorectal cancer cell metabolism to establish a drug-tolerant state during chemotherapy

Article References: UQCRC2 lactylation-mediated mitophagy orchestrates colorectal cancer cell metabolism to establish a drug-tolerant state during chemotherapy. (n.d.). https://doi.org/10.1186/s12943-026-02793-5

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02793-5

Keywords: colorectal cancer, drug-tolerant persister cells, FOLFOXIRI chemotherapy, UQCRC2, lysine lactylation, SIRT1, mitophagy, oxidative phosphorylation, metabolic reprogramming, circulating tumor cells, chemotherapy tolerance, Molecular Cancer

Dr. Papagiannakopoulos’s research is pioneering in its examination of how cancer cells adapt metabolically to stressful environments, rewiring nutrient and energy utilization pathways to survive and evade immune destruction. His laboratory employs sophisticated genome editing tools and functional genetic screens in living models, an approach that allows precise dissection of the molecular drivers of tumor progression. This methodology is crucial in distinguishing which genetic aberrations are cancer’s true vulnerabilities, offering promising avenues for the development of targeted therapies.

What sets Dr. Papagiannakopoulos apart is his integrative focus that spans metabolism and immunology, fields traditionally studied in isolation. His work elucidates how metabolic rewiring in tumor cells not only supports survival but actively shapes the immune milieu within and beyond the tumor microenvironment. By understanding these dynamic interactions, his research opens the door to manipulating tumor metabolism and immune responses concurrently, a strategy that could revolutionize anti-cancer treatments.

A novel dimension of his research investigates the crosstalk between tumors and the nervous system. Dr. Papagiannakopoulos and his team explore how cancer cells influence brain and peripheral nerve functions to modulate tumor growth, metabolic pathways, and immune system behavior. These interactions have significant clinical implications as they contribute to the cachexia syndrome frequently observed in cancer patients—manifesting as fatigue, anorexia, and severe weight loss—and currently represent a major therapeutic challenge.

Dr. Papagiannakopoulos’s involvement in the InteroCANCEption project, backed by a prestigious Cancer Grand Challenges grant, aims to decode the mechanisms by which the nervous system senses and responds to cancer throughout the body. This systemic approach to cancer biology underscores the emerging paradigm that cancer should be understood not only as a cellular and genetic disease but also as a complex disorder modulated by whole-body physiological networks.

Commenting on the appointment, Salk Institute President Gerald Joyce highlighted Dr. Papagiannakopoulos’s talent for bridging fundamental cancer biology with innovative, interdisciplinary strategies. Joyce emphasized that this alignment with Salk’s culture of curiosity-driven research and collaboration exemplifies the Institute’s mission to pioneer foundational science with the potential to yield transformative clinical breakthroughs.

Dr. Papagiannakopoulos expressed enthusiasm about joining the Salk Institute, citing its unique environment where high-risk, high-reward science thrives. He underscored the significance of integrating his expertise with the existing strengths in cancer immunobiology, metabolism, and neurobiology at Salk, particularly collaboration opportunities with the NOMIS Center and neuroscientists focusing on how cancer intersects with systemic physiology.

Among his groundbreaking contributions, Dr. Papagiannakopoulos’s recent publications in Nature unveiled therapeutic potentials by targeting proteins involved in ferroptosis resistance and immune evasion in lung and pancreatic cancer models. Ferroptosis, a regulated form of cell death driven by iron-dependent lipid peroxidation, represents an Achilles’ heel for certain tumors—disabling mechanisms that prevent ferroptosis can trigger cancer cell death. Similarly, inhibiting proteins that suppress anti-tumor immune responses unveils new immunotherapeutic strategies that could complement existing treatments, broadening the arsenal against aggressive cancers.

Dr. Papagiannakopoulos’s academic journey is distinguished by rigorous training, beginning with a Bachelor’s degree in Molecular Genetics from the University of Sussex, followed by a PhD in Molecular and Cellular Biology at the University of California, Santa Barbara. His postdoctoral work at MIT sharpened his expertise in genome engineering techniques and in vivo cancer modeling. Throughout his career, his innovative research has attracted significant funding from federal and philanthropic sources, including the National Institutes of Health and the American Cancer Society.

At the Salk Institute, Dr. Papagiannakopoulos aims to establish a multidisciplinary research program that emphasizes integrative cancer biology, emphasizing the complex interplay between genetic mutations, cellular metabolism, immune surveillance, and neural regulation. His work will further energize Salk’s Conquering Cancer Initiative, which coordinates researchers across diverse fields to develop innovative strategies targeting lethal cancers, with a focus on lung cancer among others.

Reuben Shaw, PhD, director of Salk’s NCI-Designated Cancer Center, praised Dr. Papagiannakopoulos’s rare blend of experimental prowess and biological insight. Shaw highlighted how his innovative use of in vivo genetic modeling combined with deep knowledge of tumor metabolism and immune responses, along with a novel focus on cancer’s brain-body interactions, will greatly enhance the Center’s mission to identify new cancer vulnerabilities. Beyond research, Papagiannakopoulos is also recognized as a dedicated mentor, poised to inspire the next generation of cancer scientists at Salk.

This appointment signals a bold expansion of Salk’s cancer research capabilities, poised to unravel the multifaceted nature of cancer biology. By converging metabolism, immunology, and neurobiology, Dr. Papagiannakopoulos’s interdisciplinary vision promises not only to accelerate basic scientific understanding but also to accelerate the translation of discoveries into novel, effective therapies, potentially transforming cancer treatment paradigms.

The Salk Institute itself, founded in 1960 by Jonas Salk—the developer of the first safe polio vaccine—continues its mission of pioneering foundational and high-impact biological research. Its commitment to risk-taking, curiosity-driven science remains a beacon for innovation, addressing some of society’s most urgent health challenges, including cancer. Dr. Papagiannakopoulos’s recruitment exemplifies the Institute’s ongoing leadership in marrying foundational science with translational prospects that can change medicine globally.

As Dr. Papagiannakopoulos embarks on this next chapter at Salk, the scientific community eagerly anticipates the groundbreaking discoveries that will emerge from his integrative and visionary approach to cancer biology. These efforts not only deepen our molecular understanding of cancer but also pave pathways toward innovative therapeutic interventions that may one day cure or effectively manage certain cancers that currently pose formidable clinical challenges.

Subject of Research: Cancer biology, tumor metabolism, cancer immunology, tumor-host interactions, cancer neuroscience

Article Title: Salk Institute Welcomes Dr. Thales Papagiannakopoulos to Advance Cancer Research Frontier

News Publication Date: April 2, 2026

Web References:

• Salk Institute: www.salk.edu
• InteroCANCEption Project: Cancer Grand Challenges

References:

• Papagiannakopoulos et al., Nature, recent studies on ferroptosis and anti-tumor immunity (specific citations not provided in source text)

Image Credits: Sim Singh

Keywords: Cancer metabolism, immunology, tumor microenvironment, ferroptosis, genome engineering, nervous system and cancer, tumor-host interactions, Salk Institute, lung cancer, pancreatic cancer, cancer neuroscience, cancer therapy

The research primarily focuses on the unique metabolic adaptations that cancer cells undergo, allowing them to thrive in the harsh conditions of the tumor microenvironment. Glutamine, an amino acid that is abundant in our diets, is central to many metabolic pathways, particularly in cancer metabolism. The researchers conducted various analyses to elucidate the metabolic shifts that occur in bladder cancer cells, revealing that these cells exhibit a heightened dependency on glutamine. By understanding how these metabolic pathways are altered, the researchers hope to identify potential therapeutic targets that could disrupt the relentless proliferation of cancer cells.

Central to the study is the enzyme PYCR1, which plays a crucial role in the synthesis of proline, an amino acid that is not only essential for protein synthesis but also contributes to various cellular functions. The findings indicate that PYCR1 is substantially upregulated in bladder cancer tissues when compared to normal tissues, leading to an increase in proline levels and promoting tumor growth. This upregulation suggests that PYCR1 and its associated pathways could be valuable targets for new treatment strategies aimed at inhibiting bladder cancer progression.

The multi-omics approach employed in this study integrates genomics, proteomics, and metabolomics, allowing the researchers to obtain a holistic view of the biochemical changes occurring within bladder cancer cells. By leveraging advanced technologies such as mass spectrometry and high-throughput sequencing, the team was able to generate comprehensive data sets that illustrate the intricate metabolic rewiring associated with cancer progression. This method not only enhances our understanding of the disease but also opens avenues for precision medicine tailored to individual patient profiles.

In addition to identifying the metabolic pathways altered in bladder cancer, the researchers also conducted functional validation experiments to establish the causal relationship between altered glutamine metabolism and cancer progression. Through in vitro and in vivo studies, they demonstrated that inhibiting PYCR1 led to reduced cancer cell proliferation and increased apoptosis, thereby suggesting that targeting this enzyme may provide a novel therapeutic avenue for managing bladder cancer. This is particularly relevant given the limited treatment options currently available for advanced stages of the disease.

The clinical implications of these findings could be transformative. With bladder cancer being one of the most common types of cancer worldwide, driven by factors such as smoking and exposure to certain chemicals, understanding the underlying metabolic changes in tumor cells is crucial for developing effective treatments. The research highlights the urgent need for new biomarkers to predict disease progression, which could facilitate earlier intervention and improved outcomes for patients.

As bladder cancer continues to be a major health concern, the insights gained from this study pave the way for future research focused on metabolic reprogramming as a therapeutic strategy. Therapies that can effectively target metabolic pathways have the potential to enhance the efficacy of existing treatments and reduce the harmful side effects associated with conventional therapies.

Moreover, the findings underscore the importance of a multidisciplinary approach in cancer research. By combining expertise from various fields, including biochemistry, molecular biology, and clinical medicine, researchers can gain a clearer understanding of the complexities behind cancer biology. This collaborative effort is essential for translating basic research into clinical applications that could save lives.

The study by Ding et al. also raises compelling questions about the role of diet and nutrition in cancer progression. Given that glutamine is a dietary amino acid, the research promotes a dialogue about how dietary modifications could influence tumor growth. Investigating the relationship between nutritional intake and cancer metabolism could provide valuable insights into preventive strategies and emphasize the importance of holistic approaches in cancer management.

Additionally, as research progresses, it will be crucial to identify patient populations that may benefit most from therapies targeting PYCR1 and glutamine metabolism. Stratifying patients based on their metabolic profile could lead to more personalized treatment regimens and minimize the chances of overtreatment or undertreatment.

In conclusion, the findings in this study are not only pivotal in enhancing our understanding of bladder cancer but also serve as a catalyst for innovative therapeutic approaches targeting metabolic pathways. As research endeavors to harness the full potential of metabolic modulation in cancer therapy, we may witness the emergence of novel treatment paradigms that can revolutionize the management of bladder cancer, providing hope for many patients facing this challenging disease.

The dialogue surrounding cancer metabolism is growing, and with studies like this, we inch closer to bridging the gap between basic research and clinical practice. The emphasis on metabolic reprogramming as a mechanism of cancer progression calls for further exploration and validation across various cancer types. As we move forward, it is essential to maintain focus on the intricate relationships between metabolism, genetics, and environmental factors, ultimately striving for better outcomes in cancer treatment and prevention.

In the broader context of cancer research, this study highlights a significant transition in how we perceive cancer — no longer just as a genetic disease but also as a metabolic disorder. By integrating these perspectives, future investigations can yield comprehensive strategies that address not just the genetic but also the metabolic underpinnings of cancer, prompting a much-needed evolution in cancer therapy.

Indeed, the journey of unraveling the complexities of cancer is continuous, and each study brings us one step closer to understanding and conquering this multifaceted disease. The path illuminated by this research serves as a beacon of hope for patients and healthcare providers alike, guiding the pursuit of innovative treatments anchored in scientific discovery.

Subject of Research: Metabolic reprogramming in bladder cancer progression via PYCR1

Article Title: Glutamine metabolism reprogramming promotes bladder cancer progression via PYCR1: a multi-omics and functional validation study.

Article References: Ding, X., Zhang, E., Huang, Z. et al. Glutamine metabolism reprogramming promotes bladder cancer progression via PYCR1: a multi-omics and functional validation study.
J Transl Med 23, 1277 (2025). https://doi.org/10.1186/s12967-025-07386-2

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12967-025-07386-2

Keywords: Glutamine metabolism, bladder cancer, PYCR1, multi-omics, cancer progression

SHMT2, a mitochondrial enzyme critical for one-carbon metabolism, plays a pivotal role in serine metabolism and nucleotide biosynthesis within the mitochondria. Its function is intimately tied to the synthesis of building blocks indispensable for rapidly dividing cells, such as cancer cells. By facilitating the interconversion of serine to glycine and generating one-carbon units, SHMT2 supports DNA replication, repair processes, and overall metabolic adaptability, cornerstones for cancer cell survival and expansion.

The research team led by Liberati et al. employed advanced RNA interference technologies to specifically target and suppress SHMT2 in a variety of cancer cell lines. Their rigorous experiments demonstrated that downregulation of mitochondrial SHMT2 notably curtailed cellular proliferation rates, effectively stalling tumor cell growth. What sets this approach apart is its precision—leveraging the inherent specificity of RNA molecules to disrupt mitochondrial enzyme function without broadly impairing other cellular processes.

Central to this study was the exploitation of RNA species to achieve mitochondrial enzyme inhibition. Previously, mitochondrial enzymes posed significant challenges for direct targeting, owing to the organelle’s double-membrane structure and its distinct genetic code. By harnessing RNA molecules designed to interfere with SHMT2 expression or activity within mitochondria, the researchers overcame these traditional obstacles, achieving a level of organelle-specific biochemical modulation rarely seen before.

Further analyses revealed that the inhibition of SHMT2 led to a dramatic imbalance in mitochondrial one-carbon metabolism. The depletion of one-carbon units disrupted the synthesis of nucleotides necessary for DNA replication, triggering cellular stress responses that ultimately culminated in the suppression of tumor growth. Additionally, these perturbations induced metabolic bottlenecks that cancer cells were unable to circumvent, underscoring the vulnerability of their metabolic wiring.

Importantly, the suppression of cancer cell proliferation was not accompanied by widespread cytotoxicity, suggesting a therapeutic window wherein mitochondrial SHMT2 inhibition might selectively target malignant cells while sparing normal tissue. This selective toxicity is a critical consideration in anticancer drug development, where minimizing collateral damage remains a formidable challenge.

The investigation also delved into the interplay between SHMT2 activity and cellular redox balance. SHMT2 contributes indirectly to the generation of NADPH, a key molecule in combating oxidative stress. By impairing SHMT2, cancer cells exhibited increased oxidative damage, sensitizing them to cellular apoptosis. This dual effect—metabolic disruption coupled with elevated oxidative stress—amplifies the potential efficacy of SHMT2-targeted strategies.

To validate their findings, the authors conducted in vivo experiments using mouse xenograft models implanted with human cancer cells exhibiting SHMT2 inhibition. The results confirmed that tumors with reduced SHMT2 activity grew significantly slower, translating in some cases to tumor regression. These animal studies provide vital proof-of-concept support for the development of SHMT2-targeted treatments in clinical settings.

Moreover, the study highlights the broader implications of mitochondrial metabolism in cancer biology. It challenges the traditional glycolysis-centric view of cancer metabolism by emphasizing the indispensable role of mitochondrial enzymatic pathways. This paradigm shift accentuates mitochondria not merely as energy producers but as dynamic regulators of biosynthetic and redox networks critical for tumor progression.

In light of these insights, potential therapeutic modalities might include synthetically engineered RNA molecules or small interfering RNAs designed to accumulate within mitochondria, selectively knocking down SHMT2 expression. This precision medicine approach aligns with recent advances in RNA therapeutics, which have gained momentum thanks to improved delivery platforms and chemical modifications enhancing RNA stability and cellular uptake.

The ramifications extend beyond therapy development; understanding SHMT2’s role could also inform biomarker discovery. Levels of SHMT2 expression or the integrity of mitochondrial one-carbon metabolism might serve as diagnostic indicators or predictors of treatment response in various cancers. Integrating metabolic profiling into clinical oncology practice might therefore refine patient stratification and optimize personalized treatment regimens.

Additionally, the study offers fresh perspectives regarding mitochondrial dynamics in tumorigenesis. By connecting RNA-mediated enzymatic inhibition to functional mitochondrial impairment, these findings underscore how mitochondrial dysfunction can be strategically harnessed against cancer cells. This represents a fertile ground for collaboration across molecular biology, bioinformatics, and clinical research disciplines aiming to translate these discoveries into tangible health benefits.

Future research will undoubtedly explore the molecular intricacies governing RNA import into mitochondria, specificity determinants of SHMT2 targeting, and potential resistance mechanisms that cancer cells might deploy. Addressing these questions is imperative to realizing the translational potential of RNA-driven mitochondrial interventions, particularly in heterogeneous tumor microenvironments.

In sum, Liberati and colleagues’ work shines a spotlight on mitochondrial SHMT2 as a linchpin in cancer cell proliferation and elegantly demonstrates that targeted disruption via RNA interference holds potent promise as an anticancer strategy. This novel approach exemplifies the growing trend of exploiting metabolic dependencies in cancer therapy, harnessing the power of RNA biology to unlock new frontiers in precision oncology.

As the landscape of cancer treatment evolves, the intersection of RNA technology and mitochondrial biology epitomizes a frontier ripe for innovation. By disrupting crucial mitochondrial enzymes like SHMT2 through RNA-based methods, researchers are charting a course toward sophisticated, highly selective interventions poised to outmaneuver cancer’s adaptive prowess. This study thus represents a beacon of hope and a call to action for intensified investigation into RNA-mediated modulation of cancer metabolism.

The synergy of advances in mitochondrial targeting, RNA chemistry, and cancer cell metabolism elucidated by this study paves the way for next-generation therapies that can transcend the limitations of conventional treatments. Harnessing this knowledge could ultimately lead to more effective, less toxic cancer therapeutics that improve patient outcomes and quality of life, epitomizing the future of personalized medicine.

Subject of Research: RNA-mediated inhibition of mitochondrial SHMT2 and its effects on cancer cell proliferation.

Article Title: RNA-mediated inhibition of mitochondrial SHMT2 impairs cancer cell proliferation.

Article References:
Liberati, F.R., Spizzichino, S., Di Russo, S. et al. RNA-mediated inhibition of mitochondrial SHMT2 impairs cancer cell proliferation. Cell Death Discov. 11, 369 (2025). https://doi.org/10.1038/s41420-025-02646-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02646-y

HIF-1α functions as a pivotal transcription factor that governs an array of genes facilitating metabolic recalibration, immune modulation, angiogenesis, and survival pathways under hypoxic stress. The core of this regulatory control involves oxygen-dependent hydroxylation catalyzed by two classes of enzymes: prolyl hydroxylases (PHDs) and factor inhibiting HIF (FIH). Under normoxic conditions, these hydroxylases mark HIF-1α for proteasomal degradation and suppress its transcriptional activation domains. However, the precise sequence and gradation through which these hydroxylases are deactivated as oxygen levels decline were poorly understood until now.

Employing an integrative approach combining mathematical modeling, dynamic simulation, bifurcation analysis, and rigorous experimental validation, Wang’s team constructed a quantitative regulatory network that captures the stepwise activation of HIF-1α under diminishing oxygen tensions. Their model elegantly demonstrates that HIF-1α stabilization and activation do not occur as a binary switch but rather progress in discrete stages dictated by the differential sensitivity of PHDs and FIH to oxygen. This refined understanding illuminates how cells interpret the subtle hypoxic continuum—from mild to severe hypoxia—and mount graded adaptive responses accordingly.

At the initial phase of mild hypoxia, approximately 2% oxygen, prolyl hydroxylases are selectively inhibited. This inhibition results in the accumulation of HIF-1α protein by preventing its degradation and exposes the N-terminal transactivation domain (N-TAD). The partial activation conferred by N-TAD leads to transcriptional upregulation of genes primarily involved in glycolytic metabolism enhancement and immune response suppression. These early adaptations allow cells to optimize energy production and modulate their microenvironment in response to modest oxygen shortages.

As oxygen tension further decreases to moderate levels near 0.7%, factor inhibiting HIF (FIH) activity is also impeded. With FIH inactivation, the C-terminal transactivation domain (C-TAD) of HIF-1α becomes accessible, culminating in full transcriptional activation. This stage is characterized by robust induction of angiogenic factors, promoting neovascularization to restore oxygen supply. The activation of angiogenesis at this hypoxia tier represents a strategic cellular investment in long-term survival, facilitating tissue remodeling and vascular adaptation.

Under conditions of severe hypoxia, defined as oxygen concentrations below 0.5%, HIF-1α is fully stabilized and activated at maximal levels. This state triggers a crescendo of downstream effects, including accumulation of lactate due to persistent anaerobic glycolysis, acidification of the cellular microenvironment, and ultimately, the initiation of programmed necrosis pathways. This terminal response highlights the cell’s shift from adaptation toward sacrificial processes when oxygen deprivation becomes untenable.

Intriguingly, the study identifies microRNA-182 (miR-182) as a dynamic modulator that fine-tunes HIF-1α’s transcriptional output throughout these activation stages. Acting as a “sliding regulator,” miR-182 dynamically modulates the feedback loops involving HIF-1α, PHD-2, and FIH to sharpen the sensitivity and precision of oxygen sensing. This dual feedback architecture balances positive amplification and negative regulation, enabling cells to respond to fluctuating oxygen levels with remarkable fidelity and adaptability.

The implications of this tiered hydroxylase deactivation and HIF-1α activation model are profound. By unveiling distinct transcriptional configurations tied to precise hypoxic thresholds, the work provides a mechanistic blueprint for “precision targeting” within the HIF signaling cascade. Therapeutically, this opens avenues for designing phase-specific interventions, such as selective inhibitors targeting glycolytic enzymes during mild hypoxia or anti-angiogenic agents tailored for moderate hypoxic zones, enhancing treatment specificity and efficacy.

Moreover, the advances in oxygen-sensing technologies, including spatially resolved probes capable of mapping oxygen gradients deep within tissues such as bone marrow, offer exciting opportunities to apply these insights in vivo. Understanding the spatial hypoxic heterogeneity within tumors, and how different hypoxic niches activate unique HIF-1α transcriptional programs, can inform better stratification of therapeutic modalities. Such spatial hypoxia profiling may elucidate why certain regions of tumors exhibit differential drug resistance or support immune evasion, providing critical guidance for treatment planning.

The research further highlights the importance of integrating hypoxia compartmentalization into multimodal therapy design. By accounting for the interplay between drug diffusion limitations and distinct hypoxia-driven cellular adaptations, combination regimens can be optimized to circumvent compensatory resistance mechanisms. This integrated approach holds promise to transform current monotherapies, which often fail due to incomplete hypoxia targeting, into more robust, synergistic strategies capable of effectively disrupting tumor growth and progression.

Future exploration will undoubtedly focus on expanding this regulatory network to include additional noncoding RNAs, post-translational modifications, and metabolic feedbacks that intersect with the HIF pathway. Furthermore, dissecting how cyclic and dynamic hypoxia—rather than static low oxygen—modifies HIF-1α activation patterns remains a fertile area of investigation. These refinements will consolidate our molecular understanding of cellular oxygen sensing and adaptation, accelerating the development of hypoxia-based precision medicine.

In sum, this seminal study reframes the classical view of hypoxia adaptation from a simple oxygen sensor narrative to a complex, layered regulatory choreography driven by progressive hydroxylase deactivation and sophisticated feedback control. It offers both a conceptual and practical framework to decode cellular oxygen responses, paving the way for innovative diagnostic and therapeutic advancements in diseases characterized by hypoxic stress.

Subject of Research: Cellular adaptation to graded hypoxia mediated by HIF-1α regulatory networks.

Article Title: Progressive Deactivation of Hydroxylases Controls Hypoxia-Inducible Factor-1α-Coordinated Cellular Adaptation to Graded Hypoxia

News Publication Date: 1-Apr-2025

Web References: http://dx.doi.org/10.34133/research.0651

Image Credits: Copyright © 2025 Ping Wang et al.

Keywords

Hypoxia, HIF-1α, prolyl hydroxylases, factor inhibiting HIF, oxygen sensing, cell fate, angiogenesis, metabolic reprogramming, microRNA-182, tumor microenvironment, graded hypoxia, feedback regulation